Repatha Cost in Alaska 2026: Prices, Insurance, Medicaid, and Compounded Alternatives

What Evolocumab Is and Why It Gets Prescribed in Alaska

Evolocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab allows more LDL receptors to remain active, which pulls more LDL cholesterol out of the bloodstream. Amgen markets it under the brand name Repatha.

The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy. The full prescribing information is maintained at the FDA's accessdata portal.

In Alaska, cardiovascular disease remains the leading cause of death, consistent with national CDC data showing heart disease accounts for approximately 1 in 5 adult deaths annually. The CDC's most recent mortality data confirm this pattern nationally. For high-risk Alaskans who cannot tolerate high-intensity statins or who fail to reach guideline-directed LDL targets on statins alone, evolocumab is often the next pharmacologic step.

The 2018 ACC/AHA Cholesterol Guideline recommends considering a PCSK9 inhibitor when LDL cholesterol remains at or above 70 mg/dL in very-high-risk ASCVD patients despite maximally tolerated statin plus ezetimibe. The guideline is published in JACC and accessible via PubMed. That threshold directly determines whether a prescriber in Alaska will seek prior authorization for Repatha.

How Much Repatha Actually Costs in Alaska in 2026

The brand-name cash price is approximately $580 per month at Alaska retail pharmacies in 2026. No generic evolocumab exists because biologic drugs cannot be generically substituted the same way small-molecule drugs can. A biosimilar, Amjevita (adalimumab-atto), is not the same molecule; no approved biosimilar to evolocumab has reached U.S. commercial pharmacies as of mid-2025.

That $580 figure assumes the 140 mg/mL SureClick autoinjector purchased twice monthly or the 420 mg/3.5 mL single-use Pushtronex device purchased once monthly. Both regimens carry the same monthly list price. Patients using the twice-monthly schedule fill two pens; those on the monthly schedule fill one device. Amgen's published list price information is available through the FDA label.

Cash pricing varies modestly across Anchorage, Fairbanks, Juneau, and rural Alaska pharmacy networks. Remote areas sometimes see slightly higher dispensing fees. GoodRx coupons are accepted at major Alaska chains including Carrs/Safeway, Fred Meyer, and Walmart pharmacies, and the GoodRx price for evolocumab at those locations typically tracks within 5-10% of the Amgen list price because no true generic exists to create competitive pricing pressure.

Alaska Medicaid and Repatha: The Current Coverage Gap

Alaska Medicaid does not cover Repatha (evolocumab) for most beneficiaries as of 2025-2026. This is a meaningful access barrier. Alaska Medicaid's preferred drug list excludes PCSK9 inhibitors from standard coverage, citing cost-effectiveness thresholds.

The Institute for Clinical and Economic Review (ICER) has previously analyzed PCSK9 inhibitor cost-effectiveness and found that at list prices near $580/month, these agents exceed the standard $100,000-$150,000 per quality-adjusted life-year threshold for most patient populations. ICER's methodology is described in peer-reviewed publications accessible through PubMed. This cost-effectiveness finding underlies many state Medicaid program coverage decisions, including Alaska's.

Patients enrolled in Alaska Medicaid who have documented HoFH (homozygous familial hypercholesterolemia) may qualify for a medical exception review, but approval rates for non-HoFH indications are low. Submitting a Medicaid exception request requires documented failure of at least two different statins, documented intolerance or contraindication, a current LDL value, and documentation of established ASCVD or confirmed FH diagnosis. Providers should reference the 2018 ACC/AHA guideline criteria and submit alongside relevant lipid panel data to strengthen the exception case.

Commercial Insurance Coverage in Alaska: Prior Authorization Requirements

Nearly every commercial insurance plan active in Alaska, including Premera Blue Cross, Moda Health, Aetna, Cigna, and UnitedHealthcare plans sold on the Alaska exchange, places Repatha on specialty tier with mandatory prior authorization (PA) before any claim will pay.

Standard PA criteria across Alaska commercial plans in 2025-2026 include the following requirements. The patient must have a diagnosis of ASCVD, HeFH, or HoFH confirmed by a clinician. LDL cholesterol must be documented at or above a specified threshold, typically 70 mg/dL for ASCVD or 100 mg/dL for FH without ASCVD, despite concurrent maximally tolerated statin therapy. Many plans additionally require a trial of ezetimibe 10 mg for at least 90 days before approving a PCSK9 inhibitor. The ACC/AHA guideline's stepwise LDL management algorithm, which insurers use to write PA criteria, is published in JACC at PubMed.

When a PA is approved, the patient's cost-sharing depends on their plan's specialty tier structure. Patients on high-deductible health plans (HDHPs) often face the full deductible before any coverage applies, which can mean thousands of dollars in January each year. This is where the Amgen savings card becomes strategically important.

The FOURIER Trial: The Clinical Evidence Justifying the Price

Prescribers in Alaska submit PA requests citing the FOURIER trial, and insurers evaluate those requests against the same evidence. FOURIER enrolled 27,564 patients with established cardiovascular disease and LDL cholesterol of at least 70 mg/dL on optimized statin therapy. Patients randomized to evolocumab 140 mg every two weeks or 420 mg monthly achieved a mean LDL reduction of 59% from baseline (from 92 mg/dL to 30 mg/dL) compared to placebo. The primary FOURIER results are published in the NEJM and indexed on PubMed.

The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of the evolocumab group versus 11.3% of the placebo group over a median follow-up of 2.2 years, a relative risk reduction of 15% (P<0.001). FOURIER full results: NEJM 2017, PubMed ID 28304224.

A subsequent analysis of FOURIER outcomes stratified by achieved LDL level demonstrated that patients who reached LDL values below 20 mg/dL showed no increase in adverse events compared to those with higher achieved LDL values, which addressed early safety concerns about very low LDL. This FOURIER subgroup analysis is accessible via PubMed.

The Endocrine Society and American Heart Association both recognize PCSK9 inhibition as evidence-based therapy for qualifying patients. The AHA/ACC Scientific Statement on nonstatin therapy is indexed on PubMed.

Amgen's Repatha Copay Savings Card: How It Works in Alaska

Amgen offers a copay savings card for commercially insured patients that reduces out-of-pocket cost to as little as $0 per month, up to $3 to 500 in savings annually. Enrollment is free at Amgen's patient support site. The card functions as a secondary payer: the commercial insurer pays its contracted rate, and Amgen's card covers the patient's remaining cost-share, subject to the annual cap.

Key eligibility rules apply. The patient must have commercial (private) insurance. Government program beneficiaries, including Alaska Medicaid, Medicare Part D, Medicaid managed care, and TRICARE, are not eligible. Patients who are uninsured are not eligible for the copay card but may qualify for Amgen's separate free-drug program through the Repatha Enrollment Center.

The Amgen Repatha Enrollment Center (1-844-REPATHA) coordinates both the copay card and free-drug access for uninsured patients who meet income thresholds. In Alaska, where rural patients may rely on a single regional pharmacy, Amgen also offers a mail-order fulfillment pathway through Accredo Specialty Pharmacy, which can ship to Alaska ZIP codes including rural and bush communities. Amgen patient support information is linked from the FDA label.

Compounded Evolocumab in Alaska: What the Law Actually Says

Compounded evolocumab from a 503A pharmacy is legally available to patients in Alaska. A 503A pharmacy is a state-licensed compounding pharmacy that prepares medications for individual patients upon receipt of a valid prescription from a licensed prescriber. Alaska Board of Pharmacy regulations allow 503A pharmacies to compound complex biologics including monoclonal antibodies for individual patients when a licensed practitioner has determined that a commercially available product does not meet the patient's needs.

The FDA's framework for 503A compounding is established under Section 503A of the Federal Food, Drug, and Cosmetic Act. The FDA's 503A compounding guidance is published on FDA.gov. Evolocumab is not currently on the FDA's Category 1 or Category 2 lists of drug products that may not be compounded, which means 503A pharmacies may legally compound it for individual patients with a valid prescription.

Cost is the primary driver of interest in compounded evolocumab. Where a licensed 503A pharmacy compounds evolocumab, the patient cost can be substantially below the $580/month brand list price, depending on the pharmacy's sourcing, the dosage form prepared, and whether the prescriber documents medical necessity for compounding over the branded product. Some telehealth platforms partnering with 503A pharmacies have offered compounded PCSK9 inhibitor peptides at costs ranging from $100-$250/month, though pricing varies and patients should verify current pricing directly with the dispensing pharmacy.

Three caveats apply to compounded evolocumab. First, it has not been evaluated in FDA-reviewed clinical trials at the compounding scale, so potency and sterility rely on the compounding pharmacy's own quality controls. Second, insurance will not reimburse compounded evolocumab. Third, the prescribing clinician must document clinical rationale for the compounded product. A 2023 FDA guidance document on compounding of protein drugs reinforces the need for individual clinical judgment. FDA protein compounding guidance is available on FDA.gov.

Telehealth Prescribing of Repatha in Alaska

Alaska allows telehealth prescribing of non-controlled medications, including evolocumab, by any provider licensed in Alaska or by an out-of-state provider who has established a valid patient-provider relationship with an Alaska resident. The Alaska Telehealth Workgroup and state licensure boards confirmed this framework remains in place for 2026. CMS telehealth policy guidance relevant to Alaska is published on CMS.gov.

For patients in rural Alaska, including communities accessible only by air or water, telehealth prescribing eliminates a significant geographic barrier. A clinician can review lipid panels, cardiovascular history, and prior statin trials via a synchronous video visit and issue a Repatha or compounded evolocumab prescription electronically. Alaska Medicaid telehealth rules follow federal guidelines, though as noted above, Medicaid itself does not currently cover Repatha regardless of how the prescription is generated.

Commercial insurance plans operating in Alaska generally require the same PA documentation whether the prescription originates from an in-person visit or a telehealth encounter. The telehealth prescribing pathway does not shortcut the PA process, but it does give Alaskans without local cardiology access the ability to get a specialist-level evaluation for PCSK9 inhibitor eligibility without traveling to Anchorage or Fairbanks.

Statin Step Therapy and LDL Targets: What Triggers Evolocumab Eligibility

Evolocumab is not a first-line agent. Insurance PA criteria and clinical guidelines both require documented maximally tolerated statin therapy before a PCSK9 inhibitor can be approved. High-intensity statins are rosuvastatin 20-40 mg/day and atorvastatin 40-80 mg/day, per the 2018 ACC/AHA guideline classification. The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol is indexed at PubMed.

For a very-high-risk ASCVD patient who has had two or more major cardiovascular events or one major event plus multiple high-risk conditions, the guideline recommends an LDL target below 70 mg/dL, and an LDL below 55 mg/dL may be appropriate. If that target is not achieved on maximally tolerated statin plus ezetimibe 10 mg, adding a PCSK9 inhibitor is a class IIa recommendation (Level of Evidence A). The IMPROVE-IT trial validating ezetimibe as a statin add-on before escalating therapy is indexed at PubMed.

The clinical documentation that strengthens a PA request in Alaska includes a recent fasting lipid panel (within 90 days), two documented statin trials at maximally tolerated doses, a 90-day ezetimibe trial unless contraindicated, the specific ASCVD or FH diagnosis code (ICD-10: I25.10 for ASCVD, E78.01 for FH), and the treating clinician's attestation that the branded product is medically necessary over alternatives.

Familial Hypercholesterolemia: A Special Case in Alaska

Familial hypercholesterolemia affects approximately 1 in 250 people in the general population, meaning roughly 2,800-3,000 Alaskans may carry the diagnosis based on Alaska's population of approximately 740,000. The FH prevalence estimate is supported by registry data published via NCBI. HeFH is often diagnosed based on the Dutch Lipid Clinic Network (DLCN) criteria or the Simon Broome criteria, both of which require genetic counseling access that is limited in rural Alaska.

For HeFH patients, the 2016 ACC Expert Consensus Decision Pathway specifically identifies PCSK9 inhibitors as appropriate when LDL remains above 100 mg/dL on maximally tolerated statin therapy, a lower threshold than for standard ASCVD. The ACC Expert Consensus on PCSK9 inhibitors is indexed at PubMed. For HoFH, the threshold is even broader and the FDA label permits evolocumab as an adjunct to diet and other lipid-lowering treatments including LDL apheresis.

Alaska Medicaid exception requests for HoFH carry slightly better approval odds than for ASCVD alone given the severity of the disease and the limited alternatives. A confirmed genetic diagnosis via cascade testing strengthens the exception request substantially.

Side Effects and Monitoring Relevant to Alaska Prescribers

Evolocumab's side effect profile is generally mild. Injection site reactions occur in approximately 3.2% of patients. Nasopharyngitis, upper respiratory infection, and influenza-like symptoms each occur in roughly 3-7% of patients in phase 3 data. Neurocognitive adverse events were investigated in the EBBINGHAUS trial (N=1,204), which found no significant difference in cognitive function between the evolocumab and placebo groups over a median follow-up of 19 months. EBBINGHAUS is indexed at PubMed.

No routine laboratory monitoring is required beyond the lipid panel that clinicians would obtain anyway to assess treatment response. A lipid panel at 4-12 weeks after initiation confirms LDL response. For Alaska patients managing medications through telehealth, this means a single lab draw at a local Alaska Regional Hospital, Providence, or clinic laboratory is sufficient for ongoing monitoring.

Storage requires refrigeration at 36-46°F. Repatha pens can be stored at room temperature up to 77°F for up to 30 days. For rural Alaska patients receiving mail shipments, cold-chain integrity must be confirmed. Amgen's specialty pharmacy partners use validated cold-chain shipping that includes temperature monitors, and patients should inspect the monitor on arrival before using a pen.

A Practical Decision Framework for Alaska Patients in 2026

The right path to evolocumab depends on insurance status, diagnosis, and LDL level. Here is the clinical decision sequence most likely to yield access at the lowest cost.

Commercial insurance patients should start with the PA process. Document statin trials, ezetimibe trial, current LDL, and ASCVD or FH diagnosis. Enroll in the Amgen Repatha Copay Card at the same time the PA is submitted. If approved, out-of-pocket cost could reach $0 per month. The ACC/AHA guideline algorithm supporting this step sequence is at PubMed.

Alaska Medicaid patients should first confirm current formulary status with the Alaska Division of Health Care Services, then submit a medical exception with full documentation. If the exception is denied, compounded evolocumab from a licensed 503A pharmacy represents a legal, lower-cost alternative for patients where a clinician documents need. FDA 503A compounding regulations are detailed at FDA.gov.

Uninsured Alaska patients should contact Amgen's Repatha Enrollment Center at 1-844-REPATHA to screen for the free-drug program before paying cash. If income thresholds disqualify them from the free-drug program, a licensed 503A compounding pharmacy may be the most affordable legal option. PCSK9 inhibitor cost-effectiveness analysis supporting patient access advocacy is indexed at PubMed.

Medicare Part D patients should review their plan's formulary during open enrollment each fall. Some Part D plans in Alaska cover evolocumab under tier 5 specialty with a PA. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D took effect in 2025 and may reduce exposure for Medicare patients who reach the cap. CMS guidance on Medicare Part D cost-sharing changes is at CMS.gov.